Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF

Gene Therapy volume 8, pages 300–307 (2001)Cite this article

Abstract

In this study we determined the in vivo localization of recombinant proteins expressed by intraperitoneally (i.p.) injected recombinant Semliki Forest virus (SFV) particles. Subsequently, we investigated the influence of i.p. administered SFV particles encoding recombinant murine granulocyte–macrophage colony-stimulating factor (rmGM-CSF) on intraperitoneal recruitment and activation of cells. Finally, the therapeutic effect of SFV-GM-CSF treatment on an i.p. growing ovarian tumor was determined. Intraperitoneal injections of recombinant SFV particles encoding the reporter protein luciferase resulted in a high level of luciferase activity in cells of the peritoneal lining and tumor cells in the peritoneal cavity. Low levels of luciferase activity were found in liver, spleen and lungs. Injection of SFV-GM-CSF particles resulted in a slight increase in the number of peritoneal macrophages and in a significant increase in the number of neutrophils. In contrast to multiple i.p. injections with commercially available recombinant GM-CSF, i.p. injected SFV-GM-CSF particles activated the macrophages to tumor cytotoxicity. Although treatment of tumor-bearing mice with SFV-GM-CSF particles did not result in prolonged survival, tumor growth was inhibited for 2 weeks. Our findings indicate that macrophage-activating cytokines expressed by the efficient and safe recombinant SFV system when administered i.p. may provide an immunotherapeutic treatment modality additional to current chemotherapeutic treatment of intraperitoneally growing cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Strauss JH, Strauss EG . The alphaviruses: gene expression, replication, and evolution Microbiol Rev 1994 58: 491–562

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Liljeström P, Garoff H . A new generation of animal cell expression vectors based on the Semliki Forest virus replicon Biotechnology NY 1991 9: 1356–1361

    Article  Google Scholar 

  3. Tubulekas I, Berglund P, Fleeton M, Liljeström P . Alphavirus expression vectors and their use as recombinant vaccines: a minireview Gene 1997 190: 191–195

    Article  CAS  PubMed  Google Scholar 

  4. Liljeström P . Alphavirus expression systems Curr Opin Biotechnol 1994 5: 495–500

    Article  PubMed  Google Scholar 

  5. Grabstein KH et al. Induction of macophage tumoricidal activity by granulocyte–macrophage colony-stimulating factor Science 1986 232: 506–508

    Article  CAS  PubMed  Google Scholar 

  6. Williams MA, Newland AC, Kelsey SM . Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte–macrophage colony stimulating factor following chemotherapy Br J Haematol 1997 98: 960–968

    Article  CAS  PubMed  Google Scholar 

  7. Baxevanis CN et al. Granulocyte–macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses Eur J Cancer 1997 33: 1202–1208

    Article  CAS  PubMed  Google Scholar 

  8. Selgas R et al. Immunomodulation of peritoneal macrophages by granulocyte–macrophage colony-stimulating factor in humans Kidney Int 1996 50: 2070–2078

    Article  CAS  PubMed  Google Scholar 

  9. Malik STA, Martin D, Hart I, Balkwill F . Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phophoethanolamine (MTP-PE) and recombinant GM-CSF Br J Cancer 1991 63: 399–403

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Klimp AH et al. Effect of intraperitoneally administered recombinant murine granulocyte–macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells Br J Cancer 1999 79: 89–94

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Schueler RL, Ediger R . Murine ovarian teratoma Am J Vet Res 1975 36: 341–342

    CAS  PubMed  Google Scholar 

  12. Feldman GB, Knapp RC, Order SE, Hellman S . The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma Cancer Res 1972 32: 1663–1666

    CAS  PubMed  Google Scholar 

  13. Knapp RC, Berkowitz RS . Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model Am J Obstet Gynecol 1977 128: 782–786

    Article  CAS  PubMed  Google Scholar 

  14. Liljeström P, Garoff H . A new generation of animal cell expression vectors based on the semliki forest virus replicon Biotechnology 1991 9: 1356–1361

    Article  PubMed  Google Scholar 

  15. Berglund P, Fleeton MN, Smerdou C, Liljestrom P . Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice Vaccine 1999 17: 497–507

    Article  CAS  PubMed  Google Scholar 

  16. Zhou X et al. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus Proc Natl Acad Sci USA 1995 92: 3009–3013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Klimp AH, De Vries EGE, Scherphof GL, Daemen T . Chemo-immunotherapy of ovarian cancer in a murine tumor model Anticancer Res 2000 20: 2585–2592

    CAS  PubMed  Google Scholar 

  18. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gunji Y et al. Antitumor effect induced by the expression of granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cells Cancer Lett 1996 101: 257–261

    Article  CAS  PubMed  Google Scholar 

  20. Gunji Y et al. Antitumor effect of murine colon carcinoma cells retrovirally transduced with interleukin-4 and granulocyte macrophage-colony stimulating factor genes Oncology 1997 54: 69–73

    Article  CAS  PubMed  Google Scholar 

  21. Bausero MA, Panoskaltsismortari A, Blazar BR, Katsanis E . Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF interferon-gamma J Immunother 1996 19: 113–124

    Article  CAS  Google Scholar 

  22. Qin HX, Chatterjee SK . Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine Gene Therapy 1996 3: 59–66

    CAS  PubMed  Google Scholar 

  23. Rezzani R et al. Mouse peritoneal cells as a reservoir of late dendritic cell progenitors Br J Haematol 1999 104: 111–118

    Article  CAS  PubMed  Google Scholar 

  24. Daemen T, Veninga A, Roerdink FH, Scherphof GL . Conditions controlling tumor cytotoxicity of rat liver macrophages mediated by liposomal muramyl dipeptide Biochim Biophys Acta 1989 991: 145–151

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Dutch Cancer Society (grants 94–766 and 96–1280).

Author information

Authors and Affiliations

  1. Department of Physiological Chemistry, Molecular Virology Section, Faculty of Medical Sciences, Groningen University Institute for Drug Exploration, University of Groningen, Groningen, The Netherlands

    AH Klimp, E van der Vaart, PO Lansink, S Withoff & GL Scherphof

  2. Department of Medical Oncology, Molecular Virology Section, Faculty of Medical Sciences, Groningen University Institute for Drug Exploration, University of Groningen, Groningen, The Netherlands

    EGE de Vries

  3. Department of Medical Microbiology, Molecular Virology Section, Faculty of Medical Sciences, Groningen University Institute for Drug Exploration, University of Groningen, Groningen, The Netherlands

    J Wilschut & T Daemen

Authors
  1. AH Klimp
    View author publications

    Search author on:PubMed Google Scholar

  2. E van der Vaart
    View author publications

    Search author on:PubMed Google Scholar

  3. PO Lansink
    View author publications

    Search author on:PubMed Google Scholar

  4. S Withoff
    View author publications

    Search author on:PubMed Google Scholar

  5. EGE de Vries
    View author publications

    Search author on:PubMed Google Scholar

  6. GL Scherphof
    View author publications

    Search author on:PubMed Google Scholar

  7. J Wilschut
    View author publications

    Search author on:PubMed Google Scholar

  8. T Daemen
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klimp, A., van der Vaart, E., Lansink, P. et al. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Ther 8, 300–307 (2001). https://doi.org/10.1038/sj.gt.3301385

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.gt.3301385

Keywords

This article is cited by

Search

Advanced search

Quick links